DRIVE-SHIFT: Modest Weight Gain Observed Through Wk 144 After Switch to DOR/3TC/TDF in Virologically Suppressed Adults

July 6-10, 2020; Virtual
More than 2 years after the switch to DOR/3TC/TDF, adjusted mean weight gains ranged from 1.2-1.4 kg with no evident differences by sex, race, or ethnicity. The majority of patients (~ 70%) experienced < 5% weight gain at Week 144 of the study.
Format: Microsoft PowerPoint (.ppt)
File Size: 240 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

CCO commentary by Dr. Darcy Wooten on data presented at CROI 2021 regarding integrase strand inhibitor-associated weight gain and clinical implications

Darcy Wooten, MD Released: May 5, 2021

Short video log from Dr. Bisola Ojikutu on racial disparities and social determinants of health affecting care of aging patients with HIV from Clinical Care Options (CCO)

Bisola Ojikutu, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 29, 2021 Expired: April 28, 2022

Download free slides reviewing a patient case and key data on racial disparities and social determinants of health impacting older patients with HIV

Bisola Ojikutu, MD, MPH Released: April 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue